FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Class-Action Suit Accuses Walmart, Drugmakers of Selling Contaminated Irbesartan

Dec. 12, 2018

A Florida class-action suit charges Walmart, Aurobindo Pharma, ScieGen Pharmaceuticals and Westminster Pharmaceuticals negligently allowed potentially carcinogenic blood pressure drugs onto the market.

The complaint concerns Aurobindo’s recall of the API for contamination with NDEA, a probable cancer-causing agent. Aurobindo supplied affected batches of the active ingredient to ScieGen Pharmaceuticals which used them to manufacture tablets it shipped to Westminster Pharmaceuticals.

In the lawsuit, filed in the Middle District of Florida, Illinois-based lead plaintiff Barbara Kruk accused the defendants of product liability violations, breaches of contract and implied warranty, and fraudulent concealment, among other charges.

View today's stories